Doyle Mittie

Doyle Mittie is listed in filings as Chief Medical Officer at Avalo Therapeutics, Inc.. This profile follows SEC Form 4 activity through Jun 1, 2026, including sale activity. Recent filings connect the profile to Avalo Therapeutics, Inc. (AVTX) and Cullinan Therapeutics, Inc. (CGEM). The current snapshot covers public activity from Jul 16, 2024 to Jun 1, 2026. Reported amounts are shown as $10.9K to $56.3K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.